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Fetuses, infants, and juveniles (preadults) should not be considered simply "small adults" when it
comes to toxicological risk. We present specific examples of developmental toxicants that are more
toxic to children than to adults, focusing on effects on the immune and respiratory systems. We
describe differences in both the pharmacokinetics of the developing immune and respiratory
systems as well as changes in target organ sensitivities to toxicants. Differential windows of
vulnerability during development are identified in the context of available animal models. We
provide specific approaches to directly investigate differential windows of vulnerability. These
approaches are based on fundamental developmental biology and the existence of discrete
developmental processes within the immune and respiratory systems. The processes are likely to
influence differential developmental susceptibility to toxicants, resulting in lifelong toxicological
changes. We also provide a template for comparative research. Finally, we discuss the application
of these data to risk assessment. Key words: children's health, developmental exposure,
developmental immunotoxicity, respiratory toxicity, risk assessment, windows of vulnerability.
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A review ofthe literature to date in virtually
any area ofhealth-related toxicology indicates
that an overwhelming proportion ofprevious
research and testing has been directed toward
exposure ofadults as opposed to children. Yet
it is suspected that immature (embryonic,
fetal, and juvenile) populations are at greater
risk for environmentally induced toxicity.
Therefore, safety information based solely on
adult toxicity data is unlikely to result in effec-
tive protection of our most at-risk human
populations. This paper represents a com-
bined effort ofimmunotoxicologists, respira-
tory toxicologists, allergists, and dosimetry
and risk assessment experts; we have consid-
ered the challenge ofdevelopmentally based
differences in toxicological risk to the immune
and respiratory systems as relates to research,
comparative risk assessment, and, ultimately,
effective protection ofthe human population.
A series ofpapers (1-3) defining the exist-
ing literature on developmental toxicology of
the immune and respiratory systems served as
the background for aworkshop on the topic of
critical developmental windows ofexposure.
Participants in the immune and respiratory
systems work group considered the fundamen-
tal knowledge ofimmunological and respira-
tory development, the existing dosimetry and
laboratory animal models used for toxicological
assessment as pertains to human risk, the exist-
ing developmental toxicity data, the need for
additional comparisons to identify at-risk pop-
ulations (e.g., sex comparisons), the need for
additional developmentally based pharmacoki-
netic data, and the opportunities to enhance
existing risk assessment paradigms. Despite the
relative infancy ofthe research on the issue of
differential developmental risk for the immune
and respiratory systems, this work group pro-
vided the opportunity to fully consider this
important area ofresearch, testing, and assess-
ment. It is the purpose ofthis paper to estab-
lish the merits of pursuing developmental
immunotoxicity and respiratory toxicity for
improved risk assessment and to provide a
strategy to this end. We provide a potential
template for the generation of new compara-
tive data and the incorporation ofthese data
into the risk assessment process.
The Immune System
The immune system undergoes a number of
dynamic changes during the early stages of
development in mammals. These changes
include sequential formation and expansion of
pluripotent hematopoietic stem cells in differ-
ent tissue compartments, expansion of
lineage-committed stem cells, colonization of
postnatal lymphopoietic compartments, and,
finally, maturation to immunocompetence
(4). Clearly the ramification ofenvironmental
exposures at early stages ofdevelopment could
be different when cells with different poten-
tials to produce hematopoietic progeny are the
targets ofembryotoxicity. For example, based
on inherited stem cell deficiencies, it is clear
that impairment or destruction ofpluripotent
stem cells would have a more pervasive out-
come than that which occurs with more tar-
geted single-lineage changes (5,6). However, it
is not known whether cells with greater
progenitor-producing potential are necessarily
ofequal or greater sensitivity to chemical toxi-
city than are single-lineage stem cells. As a
result, we cannot necessarily assume that the
earliest stages ofdevelopment are the most
sensitive to immunotoxicity. This will
depend on a number offactors including the
developmentally timed appearance of the
most sensitive cellular targets for agent-spe-
cific immunotoxicity. However, certain
dynamic processes during immune develop-
ment may place the system at particular
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vulnerability to modulation by a wide range
ofenvironmental factors.
After stem cell formation, the formation
and subsequent seeding oflymphoid and
myeloid cells are important early processes.
These cells, including tissue macrophages and
mast cells, are dispersed throughout the body
and are important for subsequent tissue sur-
veillance and homeostasis. This also leads to
the development of various specialized
macrophages such as alveolar macrophages and
hepatic Kupffer cells. Specialized forms of
immune cells differ not only functionally but
also in sensitivity to various toxicants.
Similarly, the maturation and selection of
thymic-derived (T) lymphocytes andantibody-
producing (B) lymphocytes proceed through a
series ofwell-defined maturational compart-
ments that could represent windows ofpoten-
tial vulnerability to toxicant exposure. Hence,
it is not surprising that later in development
when the T- and B-lymphocyte repertoires are
well established, the risk of permanent
immunotoxicity might differ from that linked
with earlyexposures; toxicant interferencewith
a dynamic process such as T-lymphocyte edu-
cation (the positive and negative selection of
Tlymphocytes in the thymus) could be more
devastating than the same toxicant exposure of
afullymaturedT-lymphocyte population.
An additional consideration is that
developmental changes in the pharmaco-
kinetics for specific toxicants could alter the
actual exposure ofequally sensitive immune
target cells during different stages ofperinatal
development. Possible developmental differ-
ences in the uptake, distribution, and metabo-
lism oftoxicants provide additional incentives
for the direct comparison ofvulnerability
across immune developmental stages.
Examples from the rodent literature indi-
cate that exposure to certain immunotoxicants
during development ofthe immune system
(i.e., pre- and early postnatal exposure) pro-
duce persistent (i.e., present in the young
and/or adult animal long after early exposure)
and potentially dramatic effects on immune
function. It is noteworthy that these effects
may be either reduced or completely absent in
adults after similar exposures. Specific exam-
ples ofhighly persistent effects in rodents after
developmental immunotoxicant exposure are
described in later sections ofthis paper as well
as in theaccompanying background paper (1).
EvidenceforDevelopmentalWmdows
ofVulnerability
Although there are many examples of
developmental immunotoxicity, the informa-
tion to date tends to be based on rather broad
categories ofdevelopment (e.g., exposure
throughout gestation or exposure during ges-
tation and lactation vs. exposure ofthe adult).
Given the relative paucity ofinformation
regarding chemicals and differential risk
during more narrow and discrete windows of
embryonic and early postnatal development,
the first challenge is one ofdefining logical
developmental windows for future compari-
son. Fortunately, this can be based on
known developmental changes occurring
within the immune system as well as on
selected immunotoxicity data. Clearly, a
standardized approach to compare specific
periods ofembryonic and juvenile periods of
development for relative immunotoxic risk
would facilitate the comprehensive riskassess-
ment process. We have attempted to identify
discrete windows of immune development
where differential immunotoxic risk is likely
to exist and through which comparative
assessment can be pursued (Figure 1). A par-
allel approach for the respiratory system is
shown in Figure 2.
Sexual
Conception Birth maturity
Migration of Colonization of Maturation Initiation of stem cells and bone marrow to immuno- Establishment of
hematopoiesis expansion of andthymus competence immunememory
progenitor cells anthms cmeec imueeor
Developmental events
Day7-9 Day9-16 Dayl1-birth Birth-day30 Day30-60
Timeline formouse/rat
Week8-1O Weekl1-16 Week 6-birth Birth-1year 1-18years
Timeline for human
Figure 1. Timeline of critical windows of exposure for immune system development: a comparison of developmental
stages forthe human, mouse, and rat. The windows represent discrete steps in the formation ofthe mature immune
system and periods in which differential vulnerabilities to immunotoxicants might be expected. Information used to
develop these windows from Landreth (63), Melchers and Rolink (64), Zon (65), Muller et al. (66), and Benoist and
Mathis (67).
Developmental process or stage
DayL3-14 Dayl5-18 Day18-20 Day19-birth Day4-14 Day14-28
Timeline for mouse/rat
Week3.5-6 Week6-17 Week 15-34 Week24-38 Week36- 28yer 2 years 2-yer
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Figure 2. Timeline of critical windows of exposure for respiratory system development, illustrated as discrete matu-
rational windows during pre- and postnatal development. The timeline permits a comparison of similar stages in the
human, mouse, and rat. These maturational stages are periods in which differential vulnerabilities to respiratory
toxicants would likely occur.
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The best examples ofknown developmental
immunotoxicants are chlordane; 2,3,7,8-tetra-
chlorodibenzo-p-dioxin (TCDD); lead;
benzo[a]pyrene (B[a]P), and diethylstilbestrol
(DES). It should be emphasized that perinatal
exposure to these chemicals produces
immunotoxicity at doses that do not affect
adults and/or produce persistent changes
which do not occur with adult exposure. The
relatively small number ofsuch known devel-
opmental immunotoxicants reflects the lim-
ited number ofchemicals and environmental
agents examined for developmental immuno-
toxicity using direct age-related comparisons
rather than the established lack ofdifferential
developmental risk across broader categories
ofenvironmental agents.
Chlordane. Chlordane is an excellent
example ofa developmental immunotoxicant
where progenitor cells appear to be preferen-
tially affected (1,7). For example, in utero
exposure of mice to chlordane results in
reduced numbers ofgranulocyte-macrophage
colony-forming units in the spleen. Macro-
phages are impaired in several functions (8).
Additionally, there are functional reductions
in the 200-day-old adult with both the
delayed-type hypersensitivity (DTH) response
and the mixed lymphocyte reaction (MLR)
depressed after exposure during gestation
(9,10). As with lead, the persistent develop-
mental immunotoxic effects ofchlordane are
observed at exposure doses that do not impair
the immunesystem ofthe mother.
TCDD. TCDD is a potent immuno-
toxicant with known effect on T-lineage cells
and on the thymus itself. Given that some
effects have been described on pre-T lym-
phocytes (11,12), it is not surprising that
TCDD would exert profound effects on the
developing immune system. Exposure of
rodents to TCDD during development
results in inhibited mitogen response, graft
versus host (GVH) reaction, skin graft rejec-
tion time, and decreased resistance to chal-
lenge with infectious agents or syngeneic
tumor cells. TCDD also causes inhibited
DTH response at 19 months ofage in rats
(13). Additionally, in vitro studies using fetal
mouse thymus cultures have suggested that
TCDD exposure can disrupt the pattern of
thymocyte maturation (14).
Lead Lead is a well-established immuno-
toxicant, with the majority ofstudies focused
on adult exposures (15-18). It was first
shown to produce potential developmental
immunotoxicity in studies by Luster et al.
(19) and Faith et al. (20). Exposure ofrats to
lead in uteroand continuing for 7 weeks post-
partum at low levels (25 and 50 ppm) pro-
duced altered humoral responses; the effect
did not appear to result from altered B-lym-
phocyte function but rather from altered
T-lymphocyte and/or macrophage activity
(19). In keeping with the likelihood oflead-
induced alteration ofT-lymphocyte function,
Faith et al. (20) found that there was a
depression in T-lymphocyte mitogenic
responses in similarly exposed young
Sprague-Dawley strain rats.
More recently, additional information
suggests that lead targets both T lymphocytes
and macrophages after early exposure. The
primary effect on T cells is a shift in the T
helper (Th) cell functional balance, with Thl
function depressed andTh2 function elevated
(15). In a dose-response comparison among
pregnant rats and rat female pups exposed
during gestation and assessed as young adults,
developing fetuses were susceptible to persis-
tent immunotoxic effects oflead at doses that
did not affect the pregnant dams (21,22).
The nature ofthe immunotoxicity was simi-
lar to that reported for exposed adults; rats
exposed in utero exhibited depressed Th1
function (e.g., reflected by a depressed DTH
response) with a concomitant elevation in
someTh2-dependent parameters.
The likelihood that different windows of
perinatal development have different risk for
lead-induced immunotoxicity has recently
received support. Preliminary data obtained
in chickens suggest that the risk ofpersistent
immunotoxicity from lead exposure is not
equal across embryonic development (i.e.,
windows ofdifferential vulnerability do exist
for lead-induced developmental immunotoxi-
city). For example, early in ovo exposure ver-
sus late in ovo exposure results in a different
spectrum of immunotoxic changes in the
younganimal (23).
B[a]P. Polycyclic aromatic hydrocarbons,
such as B[a]P, depress acquired immunity in
adult animals by interfering with effective
antigen presentation and the subsequent
clonal stimulation oflymphocytes. During
embryonic exposure ofmice to B[a]P and as
discussed by Holladay and Smialowicz (1),
there is a severe reduction in fetal thymocyte
number and maturation. Total fetal liver
hematopoietic cells were also reduced in these
animals, including numbers of both pro-T
and pro-B lymphocytes. The end result is
severe depression ofboth cell- and humoral-
mediated immune function that is highlyper-
sistent (still present at 18 months ofage).
Early B[a]IP exposure also causes depressed
MLR, GVH response, and increased tumor
frequency (24-26).
DES. Prenatal exposure of rodents to
DES results in long-term impairment of
humoral (antibody production), innate [nat-
ural killer (NK) cell activity], and cell-
mediated (T-lymphocyte mitogen, DTH,
and GVH) responses. It also causes increased
postnatal susceptibility to viral-induced mam-
mary tumors, transplanted primary tumors,
and carcinogen-induced tumors. In humans
exposed to DES during gestation, uncon-
firmed reports suggest possible alterations in
T lymphocyte and NK cell function and an
increased incidence ofautoimmune disease.
PartitoningImmune Developmentinto
TestableWindows ofDifferentialRisk
Establishment of the vertebrate immune
system requires a sequential series ofcarefully
timed and coordinated developmental events
that begin early in life and continue though
the early postnatal period. Such development
is further characterized by progressive cellular
migrations through multiple hematopoietic
compartments (i.e., yolk sac, fetal liver, bone
marrow, and thymus). It is likely that pertur-
bations or abrogations ofcritical events in this
highly regulated developmental sequence may
lead to immune dysfunctions as described for
thevarious chemical agents.
Multiple toxicant-dependent windows of
increased vulnerability may exist during
development that contribute to postnatal
consequences ofdevelopmental immunotoxi-
cant exposure. For instance, TCDD induces
fetal thymic hypocellularity (at least in part)
by selective targeting of progenitor T cells
responsible for colonizing the thymus. At the
level ofthe thymus, TCDD also causes a sig-
nificant inhibition ofthymocyte differentia-
tion. The net effect is both fewer and more
immature precursor T cells in the TCDD-
exposed fetus. Each ofthese effects may con-
tribute to postnatal immunosuppression;
however, it is unclear which effect may con-
tribute more. In addition, TCDD reduces
expression ofself-antigen-presenting mole-
cules in the thymus, an effect that may alter
normal positive and negative selection of
T cells (T-cell education) and ultimately
affect self-recognition by T cells. In this
regard, recent studies in rodents that are
genetically predisposed to the development of
autoimmune disease indicate that exposure to
TCDD during establishment ofthe immune
system causes earlier onset and increased
severityofautoimmune disease (27).
It is not known if exposure to TCDD
before, during, or after establishment ofthe
thymus rudiment may contribute more to
thymic involution and postnatal immunosup-
pression caused by this compound. Similarly,
it is not known if exposure to TCDD
between establishment ofthe fetal thymus
and birth or early in the postnatal period via
lactation may play a greater role in induction
or exacerbation of autoimmune disease in
genetically predisposed rodents. Although the
developmental period is a time ofhigh sensi-
tivity to immunotoxicant exposure, the spe-
cific mechanisms by which TCDD targets
progenitor or precursor T cells during devel-
opment are still not clear. Because TCDD
inhibits differentiation and proliferation of
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developing immune cells, additional research
evaluating cell-cycle gene expression (e.g.,
bcl-2, p53, and wee-i) in both fetal liver and
thymus at different stages ofgestation would
be useful.
In the case oflead, gestational exposure
offemale rodents at levels that do not affect
adults produces both T-cell and macrophage
alterations postnatally. There is some sugges-
tion from preliminary studies that targeted
exposure during different stages ofembry-
onic development may result in different
profiles ofpostnatal immunotoxicity. For
example, exposure of developing chick
embryos (21-day incubation time) to lead
during the first halfofembryonic develop-
ment (e.g., 5-9 days ofincubation) produces
persistent changes in macrophage function;
however, this occurs without the hallmark
decline in T-dependent function (e.g., DTH
reaction) that is characteristic ofboth full
gestational and adult exposure to lead.
However, exposure of the embryo to lead
later in development (12 days ofincubation)
results in both macrophage andT-dependent
functional deficiencies (similar to the effects
seen in rodents with full gestational expo-
sure). Given the changes occurring within
the thymus during vertebrate embryonic
development and the effects oflead on T-cell
function, the status ofthe thymus and T-cell
populations might relate to windows ofdif-
ferential developmental vulnerability for
lead-induced immunotoxicity. Such observa-
tions support the need to define and examine
specific developmental windows ofincreased
vulnerability to immunotoxicants.
With the available developmental
immunotoxicology information, it is possible
to construct a chart ofpotential windows of
vulnerability to immunotoxicants. Figure 1
illustrates the timing for key events of
immune maturation from conception to sex-
ual maturity. Comparisons are provided
among rodents and humans for the timing of
specific immunological maturation events.
Immune maturation could be divided using
several criteria; Figure 1 identifies five discrete
windows ofimmune maturation based on
landmark immunological events (e.g., thymic
colonization) and provides a potentially stan-
dardized developmental approach to evaluate
differential riskofimmunotoxicity.
Gaps inKnowledge forthe
ImmuneSysm
As discussed in the background paper (1),
only limited information is available concern-
ing relative developmental immunotoxic
effects as related to discrete windows ofearly
development. Earlygestational versus late ges-
tational versus lactational exposures have
rarely been examined in studies; evaluation of
these exposures and the associated risks would
facilitate direct immunological comparisons.
Additionally, potential two-generational
information is lacking. For example, it is not
known whether an environmentally induced
alteration in the cytokine and immune
metabolite profiles of the gestationally
exposed mother might have the potential to
influence the course ofimmune development
in the second-generational offspring.
Additionally, altered adult immune capabili-
ties could influence reproductive function
and the maintenance (e.g., protection from
immune attack) ofan allogeneic fetus in the
motherduringpregnancy.
Little information is available concerning
the possibility ofdifferential risk based on
sex. In the case oflead, preliminary data
resulting from in utero exposure to a single
dose oflead suggest that lead produces differ-
ent immunotoxic outcomes based on the sex
of the fetus (28). This suggests that at the
very least, sex is likely to influence dose-
response sensitivities, ifnot the spectrum of
immunotoxicity resulting from particular
developmental exposures.
The Respiratory System
The respiratorysystem consists ofanumber of
anatomic regions: the extrathoracic region,
including the anterior nose and the posterior
nasal passages, larynx, pharynx, and mouth;
the tracheobronchial region, consisting ofthe
trachea, bronchi, bronchioles, and terminal
bronchioles; and the alveolar-interstitial
region, consisting ofthe respiratory bronchi-
oles, the alveolar ducts and sacs with their
alveoli, and the interstitial connective tissue.
Each region can be distinguished on the basis
ofstructure, size, and function. The character-
istics ofthe airdrawn into the respiratory tract
and exhaled aregreatlyinfluenced by the mor-
phometry of the respiratory tract, which
causes numerous changes in pressure, flow
rate, direction, and humidity as air moves into
and out ofthe system. Differences in ventila-
tion rates and in the upper respiratory tract
structure and in size and branchingpatterns of
the lower respiratory tract between species and
amongdifferent ages ofpeople result in signif-
icantlydifferent patterns ofparticle deposition
and gas transport because ofthe effect ofthese
geometric variations on air-flow patterns (29).
Physicochemical characteristics ofinhaled par-
tides or gases also influence the partide dispo-
sition (encompassing the processes of
deposition, absorption, distribution, metabo-
lism, and elimination) and interact with the
anatomic and physiologic parameters such as
ventilation rate, cardiac output (perfusion),
metabolic pathways, tissue volumes, and
excretion pathways. The relative contribution
ofthese processes and interactions with the
physicochemical characteristics are affected by
the exposure concentration andduration.
Timing ofthe exposure is also important
(30). There are discrete windows ofvulnera-
bility in the development ofthe respiratory
system. To understand these windows ofvul-
nerability, four facts about the development
ofthe respiratory system are important. First,
development of the respiratory system is a
multievent process that is not restricted to
prenatal life. Although the lungs undergo
dramatic changes during the embryonic,
pseudoglandular, cannicular, and saccular
stages, the majority ofchanges to the lungs
continue postnatally. Second, only a limited
number ofmaturational events must be fin-
ished at birth for successful survival ofthe
neonate. Third, these developmental events
occur in the presence ofan increasing mass
oftotal cells. Finally, exposures to smoking,
air pollution, and repeated pulmonary infec-
tions cause lung alterations that may be diffi-
cult to distinguish from changes due to aging
alone (31).
Growth and development ofthe human
respiratory system is not complete until
approximately 18-20 years ofage (31). As the
respiratory system develops, the differences in
both airway geometry and respiratory condi-
tion are likely to affect its dosimetry and
responsiveness (32). Development of the
human respiratory system involves the differ-
entiation and proliferation ofover 40 differ-
ent cell types as well as the formation ofa
highly ordered airway branching system with
25,000 distinct terminations giving rise to
> 300 million alveoli. The development of
the lungs begins with the evaginations ofan
avascular epithelial bud and subsequent
growth into surrounding mesenchymal tis-
sues. After embryogenesis, the fetal lungs in
all mammalian species undergo three anatom-
ically distinct stages ofgrowth: pseudoglan-
dular, canalicular, and saccular. Although the
lungs have developed sufficiently to sustain
life at birth, growth is far from complete.
Greater than 80 percent ofalveoli in the adult
stage arise postnatally. In essence, lung devel-
opment is a continuum from embryogenesis
through early adulthood.
The process ofcellular differentiation,
branching morphogenesis, and overall lung
growth can be affected by exposure to chemi-
cals. The effects ofexposure on the respiratory
system are likely to be different for each
period ofdevelopment. For example, during
embryogenesis and fetal development, cell
number, type, and function ofthe airways and
alveoli may be significantly affected by expo-
sure to a diverse number ofsubstances and/or
conditions. Both embryogenesis and fetal ges-
tation represent critical periods ofcellular dif-
ferentiation and branching morphogenesis.
Because these cells continue to differentiate
and divide during the postnatal period, chem-
ical exposure during the postnatal period is
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also likely to affect the respiratory system,
albeit in a different manner, based on changes
in the process ofdifferentiation and morpho-
genesis. Because growth is largely complete by
20 years ofage, exposure to chemicals and
other factors are likely to have different
consequences in adults than in children.
Differences in airflow in the upper respi-
ratory tract, both between species and for
children versus adults, are one ofthe domi-
nant determinants oflesions in this region for
both particles and gases (33-40). Likewise,
differences in airway geometry and ventila-
tion also result in dosimetry and response dif-
ferences between children and adults to
inhaled agents in the lower respiratory tract
(39-43). These differences in dosimetry may
be important determinants ofsusceptibility
between children and adults. For example,
children have higher extrathoracic and total
deposition in the tracheobronchial region
(33,43), which may explain observations of
epidemiologic studies suggesting that children
have increased morbidity from particulate
airpollution.
Peden (2) discussed the premise that Th2
responses predominate early in development
and that this may be important in the protec-
tion of the fetus in the maternal allogeneic
environment. However, a lack ofdevelop-
ment ofand/or a blunting ofThl responses
would leave the individual with a predomi-
nant Th2 response and could predispose to
atopy. We raised the same issue earlier in this
paper concerning the effects oflead-induced
immunotoxicity where ThI responses are
depressed relative to Th2 responses. Factors
identified by Peden (2) as potentially impor-
tant in a consideration ofatopy are the poly-
cyclic aromatic hydrocarbon components of
diesel exhaust particles, environmental
tobacco smoke (ETS), early exposure to aller-
gens, diet, ozone, endotoxin, and the balance
of bacterial exposure versus antibiotic use.
Pinkerton (3) also emphasized the capacity of
specific ETS exposures to alter the airway sen-
sitivity ofrodents and the possible linkage of
similar exposures to the development of
airwayhyperresponsiveness in humans.
EvidenceforDevelopmental
Wimdows ofVulnerabilityin
theRespiratorySystem
Although a variety ofexposures during devel-
opment may affect lung function and growth,
the timing ofexposures during development
appears to be critical to the effects observed.
Exposure to toxic substances during critical
periods oflung development may have effects
thatwould not be seen ifthe same toxic expo-
sure were to occur during adulthood.
For example, maternal malnutrition
during gestation may significantly retard fetal
growth and the development of the lungs,
leading to compromised lung function
throughout life. Other examples include ETS
and mycotoxins.
ETS. Exposure to environmental tobacco
smoke in utero and during the first year oflife
affects the development of the infant lung
(44). Children have slower rates of lung
development if they are exposed to ETS
(45,46). Estimates indicate that current
maternal smoking reduces forced expiratory
volume in 1 sec (FEV1) by approximately
0.5% per year for each pack of cigarettes
smoked per day. Exposure to ETS may actu-
ally accelerate the maturation ofspecific cell
types in the fetal lung, but the effects ofsuch
a change on lung function are not clear.
Infants are most highly vulnerable to the
adverse effects ofexposure to ETS before 1
year ofage. Numerous studies have docu-
mented a consistent association between
lower respiratory tract illness and parental
smoking; this association appears to be
strongest during the first year ofan infant's
life (47-50).
Mycotoxins. The rapidly growing lungs of
young infants also appear to be especially vul-
nerable to the toxins ofcertain molds. An epi-
demiologic study in Cleveland, Ohio, found
that infants with acute pulmonary hemor-
rhage were more likelythan control infants to
live in homes with the toxigenic mold
Stachybotrys chartarum and other fungi in the
indoor air (51). Remarkably, whereas infants
under 1 year ofage developed life-threatening
pulmonary hemorrhage, adults and older
children living in the same moldy home envi-
ronments did not develop evidence ofpul-
monary bleeding. The authors suggested that
this may be because young infants' lungs are
growing very rapidly (52). In infant lungs,
protein synthesis of type IV collagen and
other endothelial basement membrane com-
ponents would be particularly sensitive to
inhibition by the trichothecene mycotoxins,
which are contained in the inhaled mold
spores (53) and are potent protein synthesis
inhibitors. Thus, exposure to these mycotox-
ins could result in focal areas ofcapillary
fragility in the infant lung, and subsequent
exposure to stressors that alter blood flow in
the lungs (such as ETS) could lead to areas of
increased capillary pressure and subsequent
stress hemorrhage ofthese fragile capillaries.
In mature mice, studies of intranasal
administration ofS. chartarum spores demon-
strated severe alveolar and interstitial inflam-
mation with hemorrhagic exudate in the
alveoli, but no overtlungbleeding (54,55).
Gaps inKnowledge forthe
RespiratorySystem
The effects ofexposure to environmental toxi-
cants on children's developing immune and
respiratory systems cannot be based on studies
in adults. In the respiratory system, cellular
differentiation, cellular proliferation, and cel-
lular physiological function are continually
changing during gestational and postnatal
growth. The sensitivity ofthese cells and their
response to environmental exposures are likely
to be completely different than that found in
the adult. The route ofdelivery ofan environ-
mental toxicant to the respiratory system is
completely different during the fetal period
compared to the postnatal period. Influences
ofpassage through other organ systems and
the vascular and maternal organ systems must
be taken into consideration. Our knowledge
base regarding perinatal exposure and critical
windows is inadequate. Future studies must
be designed to address these issues to better
understand and provide meaningful data to
benefit the health ofchildren during develop-
mentand into adulthood.
Laboratory Animal Data as a
Predictor of Human Response
Susceptibility can be influenced bydifferences
in exposure, pharmacokinetics, pharmacody-
namics, and target tissue status among species
and among the human population. Exposure
differences (e.g., differences in activities such
as hand-to-mouth behavior) were beyond the
scope ofthis work group. Because the various
species used in laboratory animal experiments
and humans may not receive identical doses
in comparable internal target tissue compart-
ments, and because the tissue dose of the
putative toxic moiety is not always propor-
tional to the applied dose ofa compound,
emphasis in risk assessment has recently been
placed on the need to distinguish clearly
between exposure concentration and dose to
critical target tissues. The term "exposure-
dose-response assessment" has been recom-
mended as more accurate and comprehensive
(56). This expression refers not only to the
determination ofthe quantitative relationship
between exposure concentrations and target
tissue dose, but also to the relationship
between tissue dose and the observed or
expected responses in laboratory animals and
humans. The process of determining the
exposure-dose-response continuum is
achieved by linking the mechanisms or criti-
cal biological factors that regulate the occur-
rence ofa particular process and the nature of
the interrelationships among these factors. As
shown in Figure 3, it is ultimately desirable to
have a comprehensive biologically based
dose-response model that incorporates the
mechanistic determinants ofchemical dispo-
sition, toxicant-target interactions, and tissue
responses integrated into an overall model of
pathogenesis (29).
Recent guidance from the U.S. Environ-
mental ProtectionAgencyprovides an analyti-
cal framework for incorporating such
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(57). Emphasis has been place on characteriz- dosimetry and toxicant-target tisst
ing the mode ofaction, defined as a chemical's Because it is the integration of th
influence on molecular, cellular, and physio- the organism and the physiochem
logical functions, and includes elucidation of ties of a chemical that leads to
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governing
ue response.
c biology of
effect, mode ofaction data will help to iden-
tify windows ofsusceptibility due to pharma-
cokinetic and pharmacodynamic differences
iical proper- between developmental stages versus those of
an adverse adults. Mode-of-action concepts echo the
basic biological tenets ofmolecular epidemiol-
ogy. First, early biologic effects from a toxic
effect are more prevalent in the population at
risk than the late events ofdisease (e.g., mor-
bidity and mortality) that were historical out-
Qualitative come measures ofinterest to risk assessment.
Second, the early event may be more specific
to the exposure than the end disease out-
comes, and third, technological advances
allow xenobiotics to be directly or indirectly
quantified by identification of some pre-
dictable dose-related biologic response
(58,59). Biomarkers, defined by the National
Academy ofSciences (60) as cellular or molec-
ular indicators of exposure, dose, or response
(or a simultaneous combination ofthese cate-
Quantitative
Figure 3. Characterization of the exposure-dose-response continuum in a risk assessment context. The process of
determining the continuum is achieved by linking the mechanisms of critical biological factors that regulate the
occurrence of a particular process and the nature of the interrelationships among these factors. It is ultimately desir-
able to have a comprehensive biologically based dose-response model that incorporates the mechanistic determi-
nants of chemical disposition, toxicant-target interactions, and tissue responses into an overall model of
pathogenesis. At the rudimentary level, response is related to exposure without consideration of internal dose, and
dose-response estimates based at this level of description necessarily incorporate large uncertainty factors to
ensure that the estimates are protective in the presence of substantial data gaps. With each progressive level, the
"black box" of dose becomes "illuminated," i.e., incorporation and integration of mechanistic determinants allow elu-
cidation of the continuum and, depending on the knowledge of model parameters and fidelity to the biological sys-
tem, a more accurate characterization of the pathogenesis process. Because of the increase in the accuracy of the
characterization with each progressive level, dose-response estimates also progress from more conservative (protec-
tive) to factually based (predictive). Reproduced from Jarabek (29) and the U.S. Environmental Protection Agency (58.
Exposure Effect
Internal Biologically Early Altered Clinical Prognostic Exposure dose 01 ~effective biological structure/ disease significance Exposure dose ~~~dose effect function
Susceptibility
Figure 4. The National Research Council schema for biological markers(60t, defined as any cellular or molecular indi-
cator of toxic exposure, adverse health effects, or susceptibility, and which represent signals-generally biochemi-
cal, molecular, genetic, immunological, or physiological-in a continuum of events between a causal exposure and
resultant disease. The schema is based on the tenets of molecular epidemiology, i.e., that early biological effects
from a toxic exposure are more prevalent in the population at risk than the late events of disease (e.g., morbidity and
mortality) that were historical outcome measures of interest to risk assessment, that the early events may be more
specific to the exposure than the end disease outcomes, and that technological advances allow xenobiotics to be
directly or indirectly quantified by identification of some predictable, dose-related biologic response. The schema is
similar to thatdepicted in Figure 3 and helps to illustrate how the basis of dose-response estimates on key precursor
events can be protective relative to assessment of later stage disease. Reproduced from the U.S. Environmental
Protection Agency(58X, Jarabek(59), and Schulte (61).
gories), can provide insights on critical mecha-
nistic aspects that are required to integrate
diverse health effects information at various
levels oforganization (e.g., cellular to popula-
tion) for risk assessment (59). As shown in
Figure 4 (58,59,61), the biomarker scheme is
essentially the same as that used for the
exposure-dose-response continuum. Thus,
biomarker data based in a mode-of-action
framework can essentially provide precursor
lesion data and can serve as a basis for a paral-
lelogram approach for extrapolation and
determination ofhuman homology for the
health effect ofinterest, as shown in Figure 5
(59). This same parallelogram approach could
be used to establish the degree ofpredictive-
ness and homology of developmental end
points versus adult end points.
Because differences in pharmacokinetics
and pharmacodynamics underlie the applica-
tion ofuncertainty factors commonly used in
risk assessment to account for requisite extrap-
olations between species and for intrahuman
variability, mechanistic research to provide the
fundamental dosimetry parameters and on tox-
icant target interactions will inform the magni-
tude ofthese factors as well and increase the
accuracy ofrisk assessments (62). Significant
progress has been made on modeling respira-
tory tract dosimetry (58) and parallel efforts
are underwayforother routes ofexposure.
Human _ --_- Human
precursor/biomarker health effect
I
A
Rat , Rat
precursor/biomarker adverse effect
Figure 5. The use of biomarker data in parallelogram
extrapolation to human homology. Reproduced from
Jarabek (59).
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Figures 1 and 2 provide schematics that
help in the evaluation ofhow well laboratory
animal data predict human response and
serve to frame research to establish human
homology. For both the immune system and
the respiratory system, data on healthy and
compromised individuals indicate that the
developing organism (prenatal to adolescent)
should not be considered a small adult.
Because ofthese qualitative and quantitative
differences, scaling practices are inappropri-
ate. There are different critical events (e.g.,
thymic education in the immune system or
morphogenesis and development ofmetabo-
lizing enzyme systems in the respiratory sys-
tem) that likely have different governing
factors ofboth dosimetry and toxicant-target
interaction (response), i.e., a different mode
of action for an agent in the developing
organism versus the adult.
In vitro data, biomarkers (or exposure,
effects, or susceptibility), or precursor lesions
may be useful to extrapolate laboratory ani-
mal or human clinical data to predict human
health outcomes (disease) from ambient
exposure scenarios via this parallelogram
approach. There are examples for both end
points where this conceptual construct has
been used successfully to establish human
homology for adults, but this has not been
extended to the developmental windows, and
it represents a key research area for both sys-
tems. Differences in dosimetry may be a key
factor to characterize to perform the parallelo-
gram approach properly. Developing more
sensitive measures than screening spirometry
(e.g., FEV1) or methacholine challenge is
important for evaluating potential perturba-
tions in the respiratory system.
In the immune system, there are three cat-
egories of responses to consider: one repre-
sents down-regulation ofthe immune system
(immunosuppression) and two represent
up-regulation ofthe immune system (hyper-
sensitivity and autoimmunity). For immuno-
suppression, inhibition of macrophage
function after low-level ozone exposure has
been measured in vitroand in bronchoalveolar
lavage that corresponds to decrements seen in
the in vivo organism (Streptococcus host-resis-
tance model). These same precursor lesions/
biomarkers have been observed in human cells
exposed to similar experimental conditions.
Inhibition ofcontact sensitivity has similarly
been illustrated after the exposure ofmice and
humans to ultraviolet B radiation.
In the respiratory system, this conceptual
framework has been filled forexposure to ETS.
Both metabolic functional changes and the cell
types affected are analogous between laboratory
animal species and humans. Adjustments for
dosimetry are required for accurate prediction,
especially when extrapolating information
from laboratory animals to humans.
Summary
This paper and the accompanying back-
ground papers (1-3) attempt to provide a
framework for the determination ofdifferen-
tial toxicological risk to the immunologic and
respiratory systems during early and juvenile
development. The basic tenet is that children
differsignificantly from adults in their biologi-
cal/physiological responses to environmental
exposures. Therefore, a systematic and com-
parative approach to developmental risk
assessment is needed. To facilitate this process,
we considered immune and respiratory devel-
opment as a series ofdiscrete windows that
represent periods ofdifferential vulnerability
to toxicant and other environmental expo-
sures. Although existing toxicological data
lend support for this specific approach, it is
also clear that the most likely benefit from
such designations would come through addi-
tional research in which comparative perinatal
toxicity data would be collected and applied
to assessment. The ultimate benefit of the
approach would be the enhanced ability to
identify and better protect at-risk populations.
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